ECT in Parkinson's disease. Changes in motor symptoms, monoamine metabolites and neuropeptides
- 90 Downloads
Electroconvulsive therapy (ECT) was given to 16 non-depressed, non-demented patients with advanced Parkinson's disease (PD). In all the patients an antiparkinsonian effect was seen, lasting for 18 months in one patient, 3–5 months in seven patients, and a few days to four weeks in eight patients. After ECT the levels of homovanillic acid and neuropeptide Y in cerebrospinal fluid (CSF) were significantly increased. The eight patients with long lasting motor improvement after ECT had significantly lower CSF-3-methoxy-4-hydroxyphenylglycol compared to the group with short lasting improvement.
Five patients developed transitory mental confusion after ECT. In these patients, and in no others, a high albumin-ratio was found already before ECT was given-an indication of blood CSF barrier damage.
Our results suggest that ECT is valuable in patients with drug refractory PD or PD with intolerance to antiparkinsonian drugs.
KeywordsParkinson's disease electroconvulsive therapy monoamine metabolites neuropeptides
Unable to display preview. Download preview PDF.
- Abrams R (1989) ECT for Parkinson's disease [editorial]. Am J Psychiatry 146(11): 1391–1393Google Scholar
- Andersen K, Balldin J, Gottfries C, Granérus A-K, Modigh K, Svennerholm L, Wallin A (1987) A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with “on off” phenomena. Acta Neurol Scand 76: 191–199Google Scholar
- Bach FW, Ekman R, Jensen FM (1986) Beta-endorphin-immunoreactive components in human cerebrospinal fluid. Regul Pept 16: 189–198Google Scholar
- Barbeau A (1980) Biochemical ageing in Parkinson's disease. In: Amaducci L (ed) Ageing of the brain and dementia. Raven Press, New York, pp 275–285Google Scholar
- Cummings JL (1992) Depression and Parkinson's disease: a review. Am J Psychiatry 149(4): 443–454Google Scholar
- Douyon R, Serby M, Klutchko B, Rotrosen J (1989) ECT and Parkinson's disease revisited: a “naturalistic” study. Am J Psychiatry 146(11): 1451–1455Google Scholar
- Ekman R, Larsson I, Malmquist M, Thorell J (1983) Radioimmunoassay of delta sleepinducing peptide using an iodinated p-hydroxyphenylpropionic acid derivate as tracer. Regul Pept 6: 371–378Google Scholar
- Ekman R, Seryenius B, Castro MG, Lowry PJ, Cederlund A-S, Bergman O, Sjögren HO (1993) Biosynthesis of corticotropin-releasing hormone in human T-lymphocytes. J Neuroimmunol 44: 7–14Google Scholar
- Faber R, Trimble MR (1991) Electroconvulsive therapy in Parkinson's disease and other movement disorders. Mov Disord 6(4): 293–303Google Scholar
- Gjerris A, Werdelin L, Gjerris F, Sorensen PS, Rafaelsen OJ, Alling C (1987) CSF-amine metabolites in depression, dementia and in controls. Acta Psychiatr Scand 75: 619–628Google Scholar
- Gottfries C-G, Bråne G, Gullberg B, Steen G (1982) A new rating scale for dementia syndromes. Arch Gerontol Geriatr 1: 311–330Google Scholar
- Hoehn M, Yahr M (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442Google Scholar
- Jori A, Dolfini E (1975) Effect on ECT and imipramine treatment on the concentration of 5-hydroxyindoleacetic acid (5HIAA) and homovanilic acid (HVA) in the cerebrospinal fluid of depressed patients. Psychopharmacologia 44: 87–90Google Scholar
- Kapur S, Mann J (1993) Antidepressant action and the neurobiologic effects of ECT: human studies. In: Coffey CE (ed) The clinical science of electroconvulsive therapy. American Psychiatric Press Inc, Washington, pp 235–250Google Scholar
- Link H, Tibbling G (1977) Principles of albumin and IgG analyses in neurological disorders. II. Relations of the concentrations of the proteins in serum and cerebrospinal fluid. Scand J Clin Lab Invest 37: 391–397Google Scholar
- Montgomery S, Åsberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382–389Google Scholar
- Öhman S (1994) Diagnostic methods for demonstration of intrathecal sythesis of immunoglobulins within the central nervous system. Thesis, LinköpingGoogle Scholar
- Rudorfer MV, Risby ED, Hsiao JK, Linnoila M, Potter WZ (1988) ECT alters human monoamines in a different manner from that of antidepressant drugs. Psychopharmacol Bull 24: 396–399Google Scholar
- Tibbling G, Link H, Öhman S (1977) Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 37: 385–390Google Scholar
- Wallengren J, Ekman R, Sundler F (1987a) Occurrence and distribution of neuropeptides in the human skin. An immunocytochemical study on normal skin and blister fluid from inflamed skin. Acta Derm Venerol 67: 185–192Google Scholar
- Wallengren J, Möller H, Ekman R (1987b) Occurrence of substance P, vasoactive intestinal peptide and calcitonin gene-related peptide in factitious and cold urticaria. Acta Dermatol Res 279: 512–515Google Scholar
- Ward C, Stern G, Pratt R, McKenna P (1980) Electroconvulsive therapy in parkinsonian patients with the “on-off” syndrome. J Neural Transm 49: 133–135Google Scholar
- Webster D (1968) Clinical analysis of the disability in Parkinson's disease. Mod Treatm 5: 257–282Google Scholar
- Widerlöv E, Lindström LH, Wahlstedt C, Walleus H, Ekman R (1988) Neuropeptide Y (NPY) and peptide Y (PYY) as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res 22: 69–79Google Scholar
- Widerlöv E, Ekman R, Jensen L, Borglund L, Nyman K (1989) Arginine vasopressin, but not corticotropin releasing factor, is a potent stimulator of adrenocorticotropic hormone in electroconvulsive treatment. J Neural Transm 75: 101–109Google Scholar